Abstract
Design of drug with prolonged therapeutic action is one of the rapid developing fields of modern medical science and required implementation of different methods of protein chemistry and molecular biology. There are several therapeutic proteins needing increasing of their stability, pharmacokinetic, and pharmacodynamics parameters. To make long-live DNA-encoded drug PEGylation was proposed. Alternatively polysialic (colominic) acid, extracted from the cell wall of E. coli, fractionated to the desired size by anion-exchange chromatography and chemically activated to the amine-reactive aldehyde form, may be chemically attached to the polypeptide chain. Conjugates of proteins and polysialic acid generally resemble properties of protein-PEG conjugates, but possess significant negative net charge and are thought to be fully degradable after endocytosis due to the presence of intracellular enzymes, hydrolyzing the polysialic acid. Complete biodegradation of the polysialic acid moiety makes this kind of conjugates preferable for creation of drugs, intended for chronic use. Here, we describe two different protocols of chemical polysialylation. First protocol was employed for the CHO-derived human butyrylcholinesterase with optimized for recovery of specific enzyme activity. Polysialic acid moieties are attached at various lysine residues. Another protocol was developed for high-yield conjugation of human insulin; major conjugation point is the N-terminal residue of the insulin’s light chain. These methods may allow to produce polysialylated conjugates of various proteins or polypeptides with reasonable yield and without significant loss of functional activity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Geyer BC, Latha Kannan L, Garnaud PE et al (2010) Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc Natl Acad Sci U S A 107:20251–20256
Rosenberg YJ, Saxena A, Sun W et al (2010) Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model. Chem Biol Interact 187:279–286
Chilukuri N, Sun W, Naik RS et al (2008) Effect of polyethylene glycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase. Chem Biol Interact 175:255–260
Levy Y, Hershfield MS, Fernandez-Mejia C et al (1988) Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with poly(ethyl-applicaene glycol) modified adenosine deaminase. J Pediatr 113:312–7
Graham LM (2003) Pegasparaginase: a review of clinical studies. Adv Drug Deliv Rev 10:1293–302
Hak LJ, Relling MV, Cheng C et al (2004) Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18:1072–7
Wang YS, Youngster S, Grace M et al (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54:547–70
Monkarsh SP, Ma Y, Aglione A et al (1997) Positional isomers of mono-pegylated interferon α-2a: isolation, characterization, and biological activity. Anal Biochem 247:434–40
Roelfsema F, Biermasz NR, Pereira AM et al (2006) Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomedicine 1:385–98
Pasut G, Veronese FM (2007) Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 32:933–61
Blick S, Curran M (2007) Certolizumab pegol. Biodrugs 21:196–201
Vorobiev I, Matskevich V, Kovnir S et al (2013) Chemical polysialylation: Design of conjugated human oxyntomodulin with a prolonged anorexic effect in vivo. Biochimie 95:264–270
Gregoriadis G, McCormack B, Wang Z et al (1993) Polysialic acids: potential in drug delivery. FEBS Lett 315:271–276
Gregoriadis G, Jain S (2010) Polysialylation: next generation to PEGylation. Control Rel Soc Newsl 2:21–23
Gregoriadis G, Jain S, Papaioannou I et al (2005) Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acid. Int J Pharma 300:125–130
Jain S, Hreczuk-Hirst DH, Laing P et al (2004) Polysialylation: the natural way to improve the stability and pharmacokinetics of protein and peptide drugs. Drug Deliv Syst Sci 4:3–9
Ilyushin D, Smirnov IV, Belogurov AA Jr et al (2013) Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc Natl Acad Sci U S A 110:1243–8
Ellman GL, Courtney KD, Andres V et al (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
Svennerholm L (1957) Quantitative estimation of sialic acids. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 24:604–611
Acknowledgments
The reported study was performed in the framework of the Russian Scientific Foundation Project no. 14-24-00106 (development, conjugation and purification of modified proteins) for IV, AB, DG, SD, AG and partially supported by Program of Presidium of the Russian Academy of Science “Molecular Cell Biology” (evaluation of BChE activity) for IS.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Smirnov, I.V., Vorobiev, I.I., Belogurov, A.A., Genkin, D.D., Deyev, S.M., Gabibov, A.G. (2015). Chemical Polysialylation of Recombinant Human Proteins. In: Castilho, A. (eds) Glyco-Engineering. Methods in Molecular Biology, vol 1321. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2760-9_26
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2760-9_26
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2759-3
Online ISBN: 978-1-4939-2760-9
eBook Packages: Springer Protocols